Helium induced organ protection and the role of circulatory factors: secretion of Caveolin to the bloodstream (HeCav) in humans.

Helium induced organ protection and the role of circulatory factors: secretion of Caveolin to the bloodstream (HeCav) in humans. - HeCav

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON40987

Enrollment

Registered

2014-03-05

Start date

2014-06-16

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardioprotection organprotection

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Non-smoking, healthy, male volunteers aged 20-55 years.

Exclusion criteria

Exclusion criteria: 1. Active smoking or smoking in the 6 months previous to the investigation; 2. Alcohol abuse or use of recreational drugs 3. Any allergic reaction on medication in the past 4. Presence of a chronic disease that is under current medical observation and needs pharmacological treatment, e.g. asthma, high blood pressure or diabetes

Design outcomes

Primary

Measure	Time frame
The main endpoints of this study are measuring cell damage by way of LDH measurements and apoptosis (eg caspase 3/8/9 activity, tunnel staining) in Human Umbilical Vein Endothelial Cells, Human Coronary Artery Endothelial Cells and rat cardiomyocytes against hypoxic induced damage by serum taken from the volunteers. Furthermore, the expression levels of Caveolin 1 and 3 in serum of the volunteers will be determined.	—

Measure

Time frame

The main endpoints of this study are measuring cell damage by way of LDH measurements and apoptosis (eg caspase 3/8/9 activity, tunnel staining) in Human Umbilical Vein Endothelial Cells, Human Coronary Artery Endothelial Cells and rat cardiomyocytes against hypoxic induced damage by serum taken from the volunteers. Furthermore, the expression levels of Caveolin 1 and 3 in serum of the volunteers will be determined.

—

Countries

Netherlands

Outcome results